iCMLf Expert Opinions

This section provides you with a selection of expert opinions from leaders in the field. 

You will find interviews with CML experts providing their personal perspectives on highlights from scientific meetings and latest scientific advancements as well as keynote presentations from iCMLf prize winners. The topics featured cover a broad range of issues from CML science to clinical practice.  

Keynote presentations from the recipients of the 2024 iCMLf Prizes

The 2024 iCMLf prize winners have been awarded their prizes during the ESH-iCMLf 26th John Goldman Conference on CML: Biology and Therapy in Prague.  After the award ceremony, they shared insights into their scientific and clinical work for CML over the past years during keynote presentations. You can view recordings of the Rowley Prize, the Goldman Prize and the iCMLf Prize acceptance speeches here.

	2024 Rowley Prize: Professor Neil Shah (USA) 2024 Goldman Prize: Professor Jeff Lipton (Canada) 2024 iCMLf Prize: Viji Venkatesh (India)

Read more

Keynote presentations from the recipients of the 2023 iCMLf Prizes

The 2023 iCMLf prize winners have been awarded their prizes during the 25th John Goldman Conference on CML: Biology and Therapy in Mandelieu (France).  After the award ceremony, they shared insights into their scientific and clinical work for CML over the past years during keynote presentations. You can view recordings of the Rowley Prize, the Goldman Prize and the iCMLf Prize keynote presentations here.

	2023 Rowley Prize: Professor Jerry Radich (USA) 2023 Goldman Prize: Professor François Guilhot (France) 2023 iCMLf Prize: Professor Irina Dyagil  / Dr Kostyantyn Kotlyarchuk (Ukraine)

Read more

ICMLf Genomics Alliance -
Goals and accomplishments through a global collaboration

Professor Susan Branford
Centre for Cancer Biology & SA Pathology, Adelaide, Australia

Read more

Non-BCR-ABL1 molecular biomarkers of prognosis in CML Dr. Shady Awad, Hematology Research Unit Helsinki, University of Helsinki (Finland) Clinical heterogeneity and biomarkers in CML Somatic mutations in CP-CML Epigenetic modifier gene mutations in CP-CML CHIP and clonal evolution in CP-CML Somatic mutations in BP-CML Fusion genes and rearrangements in CML Gene expression signatures (GES) as prognosis markers scRNA-sequencing in CML RUNX1 as an example of mutation-induced GES in BP-CML Molecular biomarkers of DMR Epigenetic modifier gene mutations as a biomarker for TFR Challenges and prospets

This talk was first presented during the  Scientific Working Group Session – ELN-EHA-SWG for CML: 'Understanding the pathogenesis of CML' at EHA 2022

Read more

Keynote presentations from the recipients of the 2022 iCMLf Prizes

The 2022 iCMLf prize winners have been awarded their prizes during the 24th John Goldman Conference on CML in Mandelieu (France).  After the award ceremony, they shared insights into their scientific and clinical work for CML over the past years during keynote presentations. You can view recordings of the Rowley Prize, the Goldman Prize and the iCMLf Prize keynote presentations here.

2022 Rowley Prize: Professor Oliver Hantschel 2022 Goldman Prize: Professor Andreas Hochhaus 2022 iCMLf Prize: Giora Sharf / Jan Geissler

Read more

Mechanisms of disease progression in chronic myeloid leukemia Dr. S. Tiong Ong, Duke-NUS Medical School Singapore & Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, NC, USA Learning goals: Understand that BP progression is characterized by a common, or 'core' transcriptome Understand that polycomb complex (PCR-)-driven processes contribute to the 'core' transcriptome Appreciate that a PCR-based model of CML progression identifies putative CP biomarkers and therapeutic strategies

This talk was first presented during the  Scientific Working Group Session – ELN-EHA-SWG for CML: 'Understanding the pathogenesis of CML' at EHA 2022

Read more

Keynote presentations from the recipients of the 2021 iCMLf Prizes

The 2021 iCMLf prize winners have been awarded their prizes during the 23nd John Goldman E-Conference on CML.  After the award ceremony, they shared insights into their scientific and clinical work for CML over the past years during keynote presentations. You can view recordings of the Rowley Prize, the Goldman Prize and the iCMLf Prize keynote presentations here.

2021 Rowley Prize: Professor Susan Branford 2021 Goldman Prize: Professor Giuseppe Saglio 2021 iCMLf Prize: Dr Damira Bayzakova

Read more

Keynote presentations from the recipients of the 2020 iCMLf Prizes

At the 22nd John Goldman E-Conference on CML the 2020 iCMLf prize winners have been awarded their prizes. During keynote presentations the prize recipients shared personal perspectives on their scientific and clinical work for CML over the past years. You can view web streams of the Rowley Prize, the Goldman Prize and the iCMLf Prize keynote presentations here.

2020 Rowley Prize: Professor Ravi Bhatia 2020 Goldman Prize: Professor Jane Apperley 2020 iCMLf Prize: Dr Sabira Kurtovic

Read more

Highlights from ASH 2016:
3 CML experts give their personal perspectives

This independent educational resource is supported by a grant from Novartis Oncology

Perspectives on molecular monitoring in CML from 
Associate Professor Susan Branford, PhD
Center for Cancer Biology
SA Pathology, Adelaide, Australia

• Treatment-free remission studies including an update of the EURO-SKI trial
• New data on optimal timing for monitoring patients after stopping therapy
• Additional chromosomal abnormalities and their impact on prognosis
• Next generation sequencing technologies 

Read more

Perspectives from Professor Jorge Cortes, MD

MD Anderson Cancer Center
University of Texas, Houston, USA

• Different aspects on treatment discontinuation including 2nd treatment discontinuation and QoL assessment
• Presentation of a new tyrosine kinase inhibitor
• Generics making it into practice
• Predictive markers and their impact on patients outcome
• Considerations for treatment discontinuation in clinical practice including AE management

Read more

Perspectives on QoL assessment in CML patients from Dr Fabio Efficace, PhD 

Fondazione GIMEMA, Rome, Italy

Northwestern University, Feinberg School of Medicine, Chicago, USA

• Importance of QoL assessment in CML
• Correlation between QoL and adherence to therapy
• Update on QoL data from the ENEST trials
• Overview of measuring instruments to assess QoL and the importance of patient-related QoL measures

Read more

Clinical Care Options (CCO)

Clinical Care Options (CCO) provides interactive online and live CME-certified continuing medical education (CME) programs and proprietary medical education technologies for healthcare professionals. Click here for information on CCO:

We are pleased to share their recent CML modules below:

• Biosimilars in Oncology: Insights into the development and evaluation process
  (Source: Understanding the expanding role of biosimilars in quality cancer care,
  June 2017)
• Ways to help patients accept biosimilars in oncology practice
  (by Sanjiv S. Agarwala, May 2017)
• Chronic Myloid Leukemia: 
  Managing Patients after failure of TKI therapy
  (by Elias Jabbour, October 2016)
• A CML Patient with Elevated BCR-ABL at 3 month:
  To switch or not to switch?
  (by Elias Jabbour, April 2015)
• Providing Optimal Care for Patients with Chronic Myeloid Leukemia
  (by B. Douglas Smith, July 2014)
• Chronic Myeloid Leukemia: Translating State-of-the-Art Practice to Patient care
  (by Jerald Radich & Neil P. Shah, May 2014)

Further Expert opinions

We are pleased to share additional expert opinions on various CML related topics with you here:

• Diagnosis and Monitoring Response in CML
  (by Professor Timothy Hughes, July 2012)
• CML - A short history of treatment since the mid 20th century
  (by Professor John Goldman, April 2012)
• Chronic Myeloid Leukemia - a perspective from India
  (by Professor Hemant Malhotra, July 2010)
• CML – Reversing the chronic phase
  (by Professor John Goldman, January 2010) 
• International Standardisation for BCR-ABL RQ-PCR in CML
  (by Dr Susan Bradford / Dr Nick Cross, August 2009)
• Hematopoetic Stem Cell Transplantation in CML
  (by Professor Alois Gratwohl, June 2009)
• GIPAP, historical perspective and current objectives
  (by Pat Garcia-Gonzalez, June 2009)